Arbutus to Present at Jefferies London Healthcare Conference

Core Insights - Arbutus Biopharma Corporation is focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection through its extensive virology expertise [1][2] - The company will present at the Jefferies London Healthcare Conference on November 21, 2024, and will host one-on-one meetings [1] - Arbutus has a pipeline that includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101, both of which are in clinical trials [2] Company Overview - Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in novel therapeutics with distinct mechanisms of action aimed at providing a functional cure for cHBV [2] - The company's strategy involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses [2] - Imdusiran has shown significant clinical data in reducing surface antigen and reawakening HBV-specific immune response, currently in two Phase 2a combination clinical trials [2] - AB-101 is being evaluated in a Phase 1a/1b clinical trial [2]